Zobrazeno 1 - 10
of 134
pro vyhledávání: ''
Autor:
Konstantin Penkov, Taofeek K. Owonikoko, Peter M. Ellis, Bruce A. Bach, Anne Sibille, Vasudha Sehgal, Choon Hee Son, Lei He, Jaimee Glasgow, Harry J.M. Groen, Junya Fujimoto, Patricia M. de Groot, Kingston Kang, Martin Dunbar, Lauren Averett Byers, Steven J. M. Gans, Dmitry Bentsion
Publikováno v:
Clinical Cancer Research, 27(14), 3884-3895. AMER ASSOC CANCER RESEARCH
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients and Methods: Patients were randomi
Autor:
Nina L. Jebsen, Brynjar Mauseth, Ketil André Camilio, Ahmad Awada, George Lazaridis, Christiane Jungels, Hamina Patel, Aurélien Marabelle, Vibeke Sundvold, Fabienne Hermitte, Delphine Loirat, James Spicer, Øystein Rekdal, Berit Nicolaisen, R Kristeleit, Paal Brunsvig, Andrew Saunders, Dag Erik Jøssang, Jérôme Galon, Baldur Sveinbjørnsson, Jean Francois Baurain
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. xx, no.xx, p. xx (2021)
Purpose: LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced s
Autor:
Vincenzo Di Lauro, Andrea Gombos, Ines Deleu, Matthew Barber, Bettina Müller, Roswitha Kammler, Jacquie Chirgwin, Caterina Fumagalli, Guy Jerusalem, Edda Simoncini, Katsumasa Kuroi, Meredith M. Regan, Christel Fontaine, Isabella Leone, Massimo Barberis, Marta Rita Reforgiato, Marco Colleoni, Stefan Aebi, Erika Hitre, Kathryn P. Gray, Paola Rafaniello Raviele, Joaquín Gavilá, Aron Goldhirsch, Angelo Di Leo, Per Karlsson, Elena Guerini-Rocco, Seamus O'Reilly, Elisabetta Munzone, Patrick Neven, Sibylle Loibl, Giuseppe Viale, Alastair M. Thompson, Marie-Pascale Graas
Publikováno v:
Clinical Cancer Research. 27:504-512
Purpose:Women with hormone receptor–positive early breast cancers have a persistent risk of relapse and biomarkers for late recurrence are needed. We sought to identify tumor genomic aberrations associated with increased late-recurrence risk.Experi
Autor:
Joyce Cheng, Whitney S. Helms, Adnan A. Jaigirdar, Marc R. Theoret, Kwadwo Korsah, Atiqur Rahman, Julia A. Beaver, Rajiv Agarwal, Salaheldin S. Hamed, Hong Zhao, Harpreet Singh, Anwar Goheer, Yangbing Li, Jiang Liu, Sonia Singh, John K. Leighton, Xing Wang, Richard Pazdur, Shenghui Tang, Flora Mulkey, Rajan Pragani
Publikováno v:
Clin Cancer Res
On June 15, 2020, the FDA granted accelerated approval to lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Approval was granted on the ba
Autor:
Sarah Attwell, David M. Nanus, Eric Campeau, Sanjay Lakhotia, Margo Snyder, Michael T. Schweizer, Lisa Bauman, Rahul Aggarwal, Allan J. Pantuck, Joshi J. Alumkal, Felix Y. Feng, Elisabeth I. Heath, Eric J. Small, Wassim Abida, Karen Norek
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 20
Purpose:ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide was evaluated in a phase Ib/IIa study in metastatic castratio
Autor:
Julie Switzky, Gerald Steven Falchook, Monica M. Mita, Russell Z. Szmulewitz, Swamy Yeleswaram, Wael A. Harb, Moshe Talpaz, Shilpa Gupta, Razelle Kurzrock, Justin M. Watts, Julio Antonio Peguero, Gongfu Zhou, Phillip Liu, Amitkumar Mehta, Marcus Smith Noel, Seth Rosen, Ryan D. Cassaday, Patricia LoRusso, Catherine C. Coombs, Fred Zheng, Sarina Anne Piha-Paul, David Smith
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 6
Clin Cancer Res
Clin Cancer Res
Purpose: Bromodomain and extraterminal (BET) proteins are key epigenetic transcriptional regulators, inhibition of which may suppress oncogene expression. We report results from 2 independent first-in-human phase 1/2 dose–escalation and expansion,
Autor:
Cinta Hierro, Alain C. Mita, Andrés Cervantes, Mark M. Awad, Josep Tabernero, Italo Poggesi, Rastilav Bahleda, Victor Moreno, Nancy Chan, Antoine Italiano, Ademi E. Santiago-Walker, Trilok V. Parekh, Emiliano Calvo, Jeffrey R. Infante, Alexander I. Spira, Ramaswamy Govindan, Bob Zhong, Martha Gonzalez, Hong Xie
Publikováno v:
Clinical Cancer Research. 25:4888-4897
Purpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective we
Autor:
Laurie K Pearson, Charlene C. Kabel, Paul M. Barr, Bruce D. Cheson, Chaitra S. Ujjani, Danielle M. Brander, Anthony R. Mato, Ryan Jacobs, Joanna Rhodes, Allison M. Winter, Amy A Kirkwood, Nicole Lamanna, Brian T. Hill, Alan P Skarbnik, Frederick Lansigan, John M. Pagel, Maryam Sarraf Yazdy, AnnaLynn M. Williams, Anna Schuh, Andre Goy, Hande H. Tuncer, Stephen J. Schuster, Christopher P. Fox, Colleen Dorsey, Sivraj Muralikrishnan, Mazyar Shadman, Toby A. Eyre, Arun K Singavi, John N. Allan, Nirav N. Shah, Catherine C. Coombs, Hannah Morse, Neil Bailey, Andrea Sitlinger, Chadi Nabhan, Lindsey E. Roeker
Publikováno v:
Clin Cancer Res
Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates
Autor:
Nikolaus Schultz, Yaelle Tuvy, Zoe Goldberg, Michael F. Berger, Geoffrey Y. Ku, Marinela Capanu, Laura H. Tang, Sree Bhavani Chalasani, Joanne F. Chou, Jaclyn F. Hechtman, Mark A. Schattner, Elizabeth Won, Michelle S. Boyar, David P. Kelsen, Walid K. Chatila, David H. Ilson, Azfar Basunia, David B. Solit, Avni M. Desai, Yelena Y. Janjigian
Publikováno v:
Clin Cancer Res
Purpose: VEGFR2-directed therapy is commonly used to treat metastatic esophagogastric cancer, but disease progresses in most patients within months. Therapeutic resistance is likely mediated in part by co-occurring amplifications of the genes for mul
Autor:
Jean-David Fumet, Sandy Chevrier, Aurélie Lagrange, Laurent Arnould, Romain Boidot, Fanny Ledys, Valentin Derangère, Corentin Richard, Bruno Coudert, Caroline Truntzer, Laure Favier, François Ghiringhelli
Publikováno v:
Clinical Cancer Research. 25:957-966
Purpose: Immune checkpoint inhibitors revolutionized the treatment of non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies. PD-L1 assessment and tumor mutational burden (TMB) are available tools t